Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Gyn4.5
Gynostemma – Forschung
Überwiegend Mechanismus / Beobachtung
15 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Gynostemma sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2006–2026 mit einer typischen Studiengröße von 584 Teilnehmenden.
Basierend auf 15 Studien · 1 Meta-Analyse · 8 RCTs · 600 Teilnehmende insgesamt
Einfach gesagt: Discussion Combined clinical and mechanistic findings demonstrate that Gynostemma pentaphyllum provides effective glycemic control through multi-target pharmacological mechanisms, solidifying its potential as a comprehensive therapeutic approach for diabetes management.
Wang R, Wang Y, Mo Y, Zhang H, Ma G. · Frontiers in pharmacology (2026)
Gynostemma pentaphyllum significantly reduced FPG (MD = -0.79 mmol/L, 95% CI = -1.08 to -0.51), HbA1c (MD = -1.01%, 95% CI = -1.41 to -0.61), and 2hPG (MD = -0.90 mmol/L, 95% CI = -1.95 to -0.15).
Long-term and monotherapy treatments showed superior efficacy.
The mechanistic review revealed hypoglycemic effects via multiple pathways, including enhanced glucose uptake, reduced glucose production, increased insulin secretion, and improved insulin resistance.
Einfach gesagt: Conclusion The findings presented may establish a foundation for subsequent clinical trials for the development of specific gypenosides as antidiabetic therapies for the betterment of human health.
Lee YZ, Kow ASF, Lee QL, Lim LWC, Yusof R, Tham CL, Ho YC, Lee MT. · Naunyn-Schmiedeberg's archives of pharmacology (2025)
Gypenosides can modulate various key pathways associated with diabetes pathogenesis, including PI3K/Akt, PPARγ, NF-κB, AMPK and PDX1, hence contributing to their antidiabetic properties.
Nevertheless, there is a paucity of research on gypenosides in clinical settings, with existing studies being mainly conducted on animal models and in vitro.
Future studies with the focus on the isolation and purification of specific gypenosides, as well as the exploration on the probable pharmacological effect and molecular mechanisms behind the biological actions are necessary.
Einfach gesagt: We examine the current research limitations and prospective directions for Gyps as potential therapeutic drugs or functional supplements.
Li X, Chen Y, Wang R, Cao B, Deng T, Han J, Yang M. · Frontiers in pharmacology (2025)
In the past 2 decades, a growing body of evidence has demonstrated that Gyps are crucial for the regulation of metabolic homeostasis, the reduction of oxidative stress and inflammation, the protection of the cardiovascular and hepatic systems, and the exhibition of anti-cancer potential.
However, obstacles such as limited oral bioavailability, a lack of standardized extracts, and insufficient clinical data restrict the translational potential of Gyps.
Recent developments in the pharmacological effects of Gyps, such as the biological characteristics of Gynostemma pentaphyllum and the pharmacokinetic and toxicological properties of Gyps, are summarized in this review.
Einfach gesagt: It is anticipated that these theoretical foundations will provide a useful reference for the future development and application of natural polysaccharides in functional foods and pharmaceuticals.
Hu X, Wang W, Zhang D, Tian X, Zhang A, Xu J, Feng F, Li W, Kikuchi T, Zhang J. · International journal of biological macromolecules (2025)
In recent decades, Gynostemma pentaphyllum polysaccharides (GPP) have been widely studied for their various health benefits and potential economic value.
However, there are relatively few reviews documenting these GPP.
Therefore, this paper reviews the research progress of GPP in terms of their sources, isolation and purification, structural characterization, bioactivity, conformational relationships, and applications.
Einfach gesagt: Future studies focusing on isolating and purifying novel gypenosides and investigations on exploring the potential molecular mechanism underlying their biological activities are warranted, which may serve as a foundation for further clinical trials for the betterment of human health.
Liang G, Lee YZ, Kow ASF, Lee QL, Cheng Lim LW, Yusof R, Tham CL, Ho YC, Lee MT. · European journal of pharmacology (2024)
To date, preclinical studies have demonstrated the therapeutic effects of gypenosides in alleviating neuropsychiatric disorders like depression, Parkinson's disease, Alzheimer's disease, secondary dementia, stroke, optic neuritis, etc.
Pharmacological studies have discovered that gypenosides can modulate various major signaling pathways like NF-κB, Nrf2, AKT, ERK1/2, contributing to the neuroprotective properties.
However, there is a dearth of clinical research on gypenosides, with current investigations on the compounds being mainly conducted in vitro and on animals.
Einfach gesagt: A small meta-analysis (15 studies) reported Gynostemma lowers triglycerides and raises HDL cholesterol; the paper is mostly preclinical (HFD mice + metabolomics).
Li Y et al. · Am J Chin Med (2023)
Pooled analysis: lower triglycerides, higher HDL cholesterol
Small (15-study) meta-analysis; human-only effect size not specified
Embedded in a mostly-preclinical paper (mouse mechanism: gut microbiota / tryptophan)
Einfach gesagt: A small crossover RCT (n=16) found Gynostemma (450mg) improved exercise performance and altered mitochondrial markers in healthy untrained males.
Nayyar D et al. · Nutrients (2023)
Improved exercise performance and mitochondrial markers